BioSpace News Archive

Seer Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022.

Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced that its management team will present at the following investor conferences.

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time.

Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2022 , after market close on March 2, 2022.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 2, 2022.

Pfizer Inc. and BioNTech SE announced that following a request from the U.S. Food and Drug Administration the companies have initiated a rolling submission seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, in response to the urgent public health need in this population.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on January 31, 2022, the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 525,600 shares of its common stock to four new employees under the ImmunoGen, Inc.

Today, the U.S. Food and Drug Administration is announcing a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 15 to discuss the request for emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age.

Production of normal and effective voice requires an efficient opening and closing of oropharyngeal and nasopharyngeal connecting passageway, often called velopharyngeal passageway.